Transcriptomic analysis of the NCI-60 cancer cell lines

Comptes Rendus - Biologies

Volumn 326, Issue 10-11, 2003, Pages 909-920

  Weinstein, John N ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bioinformatics; Cancer; Genomic; NCI 60 cell lines; Pharmacology; Proteomics

Indexed keywords

ALKYLATING AGENT; ASPARAGINASE; COMPLEMENTARY DNA; DNA TOPOISOMERASE INHIBITOR; GYRASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; PLATINUM DERIVATIVE;

CANCER; GENOME; RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CANCER GENETICS; COMPUTER PROGRAM; DATA BASE; DRUG DETERMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE MAPPING; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; PHARMACOGENOMICS; PROTEIN TARGETING; UNITED STATES;

EID: 0345860907     PISSN: 16310691     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crvi.2003.08.005     Document Type: Article

References (55)

1. J.N. Weinstein, Linking drugs and genes: Pharmacogenomics, pharmacoproteomics, bioinformatics, and the NCI-60, in: C. Brenner, D.J. Duggan (Eds.), Oncogenomics: Molecular approaches to cancer, New York (in press).
2. M.R. Emmert-Buck, R.F. Bonner, P.D. Smith, R.F. Chuaqui, Z. Zhuang, S.R. Goldstein, R.A. Weiss, L.A. Liotta, Laser capture microdissection, Science 274 (1996) 998-1001.
3. A. Koutsoukos, L. Rubinstein, D. Faraggi, S. Kalyandrug, J.N. Weinstein, K.D. Paull, K.W. Kohn, R.M. Simon, Discrimination techniques applied to the NCI in vivo antitumor drug screen: Predicting biochemical mechanism of action, Stat. Med. 13 (1994) 719-730.
4. L.M. Shi, J.K. Lee, Y. Fan, M. Waltham, D.T. Andrews, U. Scherf, K.D. Paull, J.N. Weinstein, Mining and visualizing large anticancer drug discovery databases, J. Chem. Inf. Comput. Sci. 40 (2000) 367-379.
5. O. Keskin, I. Bahar, R.L. Jernigan, J.A. Beutler, R.H. Shoemaker, E.A. Sausville, D.G. Covell, Characterization of anti-cancer agents by their growth inhibitory activity and relationships to mechanism of action and structure, Anticancer Drug Des. 15 (2000) 79-98.
6. M.R. Boyd, The future of new drug development, in: J.E. Neiderhuber Ed.), Current Therapy in Oncology, Philadelphia, 1992.
7. K.D. Paull, R.H. Shoemaker, L. Hodes, A. Monks, D.A. Scudiero, L. Rubinstein, J. Plowman, M.R. Boyd, Display and analysis of patterns of differential activity of drugs against human tumor cell lines, Development of mean graph and COMPARE algorithm, J. Natl Cancer Inst. 81 (1989) 1088-1092.
8. M. Gupta, A. Fujimori, Y. Pommier, DNA topoisomerase I, Biochim. Biophys. Acta 1262 (1995) 1-14.
9. F. Leteurtre, D.L. Sackett, J. Madalengoitia, G. Kohlhagen, T. Macdonald, E. Hamel, K.D. Paull, Y. Pommier, Azatoxin derivatives with potent and selective action on topoisomerase II, Biochem. Pharmacol. 49 (1995) 1283-1290.
10. F. Leteurtre, G. Koldhagen, K.D. Paull, Y. Pommier, Topoisomerase II inhibition by anthrapyrazoles, DuP 937 & DuP 941 (Losoxanthrone) and cytotoxicity in the NCI cell screen, J. Natl Cancer Inst. 86 (1994) 1239-1244.
11. E. Solary, F. Leteurtre, K.D. Paull, D. Scudiero, E. Hamel, Y. Pommier, Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent, Biochem. Pharmacol. 45 (1993) 2449-2456.
12. H.M. Koo, A. Monks, A. Mikheev, L.V. Rubinstein, M. Gray Goodrich, M.J. McWilliams, W.G. Alvord, H.K. Oie, A.F. Gazdar, K.D. Paull, H. Zarbl, G. Vande Woude, Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes, J. Natl Cancer Inst. 56 (1996) 5211-5216.
13. G. Kohlhagen, K. Paull, M. Cushman, P. Nagafufuji, Y. Pommier, Protein-linked DNA strand breaks induced by NSC 314622, a non-camptothecin topoisomerase I poison, Mol. Pharmacol. 54 (1998) 50-58.
14. E.S. Cleaveland, A. Monks, A. Vaigro-Wolff, D.W. Zaharevitz, K. Paull, K. Ardalan, D.A. Cooney, H. Ford Jr., Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the compare program, Biochem. Pharmacol. 49 (1995) 947-954.
15. J.M. Freije, J.A. Lawrence, M.G. Hollingshead, A. de la Rosa, V. Narayanan, M. Grever, E.A. Sausville, K. Paull, P.S. Steeg, Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines, Nature Med. 3 (1997) 395-401.
16. R. Bai, K.D. Paull, C.L. Herald, L. Malspeis, G.R. Pettit, E. Hamel, B. Halichondrin, homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data, J. Biol. Chem. 266 (1991) 15882-15889.
17. E. Hamel, C.M. Lin, J. Plowman, H.K. Wang, K.H. Lee, K.D. Paull, Antitumor 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives. Interactions with tubulin, Biochem. Pharmacol. 51 (1996) 53-59.
18. S.C. Kuo, H.Z. Lee, J.P. Juang, Y.T. Lin, T.S. Wu, J.J. Chang, D. Lednicer, K.D. Paull, C.M. Lin, E. Hamel, et al., Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4′-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin, J. Med. Chem. 36 (1993) 1146-1156.
19. K.D. Paull, C.M. Lin, L. Malspeis, E. Hamel, Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data, Cancer Res. 52 (1992) 3892-3900.
20. K. Wosikowski, D. Schuurhuis, K. Johnson, K.D. Paull, T.G. Myers, J. Weinstein, S.E. Bates, Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns, J. Natl Cancer Inst. 89 (1997) 1505-1513.
21. J.N. Weinstein, K.W. Kohn, M.R. Grever, VN. Viswanadhan, L.V. Rubinstein, A.P. Monks, D.A. Scudiero, L. Welch, A.D. Koutsoukos, A.J. Chiausa, K.D. Paull, Neural computing in cancer drug development: predicting mechanism of action, Science 258 (1992) 447-451.
22. W.W. van Osdol, T.G. Myers, K.D. Paull, K.W. Kohn, J.N. Weinstein, Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents, J. Natl Cancer Inst. 86 (1994) 1853-1859.
23. W.W. van Osdol, T.G. Myers, J.N. Weinstein, Neural network techniques for the informatics of cancer drug discovery, Methods in Enzymology 321 (2000) 369-395.
24. J.N. Weinstein, T.G. Myers, J.K. Buolamwini, K. Raghavan, W. van Osdol, J. Licht, V.N. Viswanadhan, K.W. Kohn, L.V. Rubinstein, A.D. Koutsoukos, A.P. Monks, D.A. Scudiero, N.L. Anderson, D. Zaharevitz, B.A. Chabner, M.R. Grever, K.D. Paull, Predictive statistics and artificial intelligence in the US National Cancer Institute's drug discovery program for cancer and AIDS, Stem Cells 12 (1994) 13-22.
25. J.N. Weinstein, T.G. Myers, P.M. O'Connor, S.H. Friend, A.J. Fornace, K.W. Kohn, T. Fojo, S.E. Bates, L.V. Rubinstein, N.L. Anderson, J.K. Buolamwini, W.W. van Osdol, A.P. Monks, D.A. Scudiero, E.A. Sausville, D.W. Zaharevitz, B. Bunow, V.N. Viswanadhan, G.S. Johnson, R.E. Wittes, K.D. Paull, An information-intensive approach to the molecular pharmacology of cancer, Science 275 (1997) 343-349.
26. Y. Fan, L.M. Shi, T.G. Myers, K.W. Kohn, Y. Pommier, J.N. Weinstein, Quantitative structure-antitumor activity relationships of camptothecins: cluster analysis and genetic algorithm-based studies, J. Med. Chem. 44 (2001) 3254-3263.
27. L.M. Shi, Y. Fan, T.G. Myers, P.M. O'Connor, K.D. Paull, S.H. Friend, J.N. Weinstein, Mining the NCI anticancer drug discovery databases: Genetic function approximation for the QSAR study of anticancer ellipticine analogues, J. Chem. Inf. Comput. Sci. 38 (1998) 189-199.
28. L.M. Shi, Y. Fan, T.G. Myers, M. Waltham, K.D. Paull, J.N. Weinstein, Mining the anticancer activity database generated by the US National Cancer Institute's drug discovery program using statistical and artificial intelligence techniques, J. Chem. Inf. Comput. Sci. (1998).
29. L.M. Shi, T.G. Myers, Y. Fan, P.M. O'Connor, K.D. Paull, S.H. Friend, J.N. Weinstein, Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity, Mol. Pharmacol. 53 (1998) 241-251.
30. A.A. Rabow, R.H, Shoemaker, E.A. Sausville, D.G. Covell, Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities, J. Med. Chem. 45 (2002) 818-840.
31. D. Rogers, A.J. Hopfinger, Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships, J. Chem. Inf. Comput. Sci. 34 (1994) 854-866.
32. G.W.A. Milne, M.C. Nicklaus, J.S. Driscoll, S. Wang, D. Zaharevitz, National Cancer Institute drug information system 3D database, J. Chem. Inf. Comput. Sci. 34 (1994) 1219-1224.
33. M. Alvarez, K.D. Paull, C. Hose, J.S. Lee, J.N. Weinstein, M. Grever, S. Bates, T. Fojo, Generation of a drug resistance profile by quantitation of MDR-1/P-glycoprotein expression in the cell lines of the NCI anticancer drug screen, J. Clin. Investig. 95 (1995) 2205-2214.
34. M.A. Izquierdo, R.H. Shoemaker, M.J. Flens, G.L. Scheffer, L. Wu, T.R. Prather, Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines, Int. J. Cancer 65 (1996) 230-237.
35. J.S. Lee, K.D. Paull, M. Alvarez, C. Hose, A. Monks, M. Grever, A.T. Fojo, S.E. Bates, Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen, Molec. Pharmacol. 46 (1994) 627-638.
36. L. Wu, A.M. Smythe, S.F. Stinson, L.A. Mullendore, A. Monks, D.A. Scudiero, K.D. Paull, A.D. Koutsoukos, L.V. Rubinstein, M.R. Boyd, R.H. Shoemaker, Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening, Cancer Res. 52 (1992) 3029-3034.
37. K.V. Chin, I. Pastan, M.M. Gottesman, Function and regulation of the human multidrug resistance gene, Adv. Cancer Res. 60 (1993) 157-180.
38. M.M. Gottesman, I. Pastan, Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu. Rev. Biochem. 62 (1993) 385-427.
39. P.M. O'Connor, J. Jackman, I. Bae, T.G. Myers, S. Fan, M. Mutoh, D.A. Scudiero, A. Monk, E.A. Sausville, J.N. Weinstein, S. Friend, J. Fornace, K.W. Kohn, Characterization of the p53-tumor suppressor pathway in cells of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents, Cancer Res. 57 (1997) 4285-4300.
40. J.N. Weinstein, Fishing expeditions, Science 282 (1998) 627-628.
41. J.N. Weinstein, 'Omic' and hypothesis-driven research in the molecular pharmacology of cancer, Curr. Opin. Pharmacol. 2 (2002) 361-365.
42. T.G. Myers, M. Waltham, G. Li, J.K. Buolamwini, D.A. Scudiero, L.V. Rubinstein, K.D. Paull, E.A. Sausville, N.L. Anderson, J.N. Weinstein, A protein expression database for the molecular pharmacology of cancer, Electrophoresis 18 (1997) 647-653.
43. G. Li, M. Waltham, E. Unsworth, A. Treston, J. Mushine, N.L. Anderson, K.W. Kohn, J.N. Weinstein, Rapid protein identification from two-dimensional polyacrylamide gels by MALDI mass spectrometry, Electrophoresis 18 (1997) 647-653.
44. W.C. Reinhold, H. Kouros-Mehr, K.W. Kohn, A.K. Maunakea, S. Lababidi, A. Roschke, K. Stover, J. Alexander, P. Pamazis, L. Miller, E. Liu, I.R. Kirsch, Y. Urasaki, Y. Pommier, J.N. Weinstein, Apoptotic susceptibility of cancer cells selected for camptothecin resistance: Gene expression profiling, functional analysis, and molecular interaction mapping, Cancer Res. 63 (1993) 1000-1011.
45. S. Nishizuka, S.-T. Chen, F.G. Gwadry, J. Alexander, U. Scherf, W.C. Reinhold, M. Waltham, L. Charboneau, L. Young, K.J. Bussey, S. Kim, S. Lababidi, J.K. Lee, S. Pittaluga, P.J. Munson, E. Petricoin, L.A. Liotta, S.M. Hewitt, M. Raffeld, J.N. Weinstein, Diagnostic markers that distinguish colon and ovarian adenocarcinomas: Identification by genomic, proteomic, and tissue array profiling, Cancer Res., in press.
46. D.T. Ross, U. Scherf, M.B. Eisen, C.M. Perou, C. Rees, P. Spellman, V. Iyer, S.S. Jeffre, M. Van de Rijn, M. Waltham, A. Pergamenschikov, J.C.F. Lee, D. Lashkari, D. Shalon, T.G. Myers, J.N. Weinstein, D. Botstein, P.O. Brown, Systematic variation in gene expression patterns in human cancer cell lines, Nat. Genet. 24 (2000) 227-235.
47. U. Scherf, D.T. Ross, M. Waltham, L.H. Smith, J.K. Lee, L. Tanabe, K.W. Kohn, W.C. Reinhold, T.G. Myers, D.T. Andrews, D.A. Scudiero, M.B. Eisen, E.A. Sausville, Y. Pommier, D. Botstein, P.O. Brown, J.N. Weinstein, A gene expression database for the molecular pharmacology of cancer, Nat. Genet. 24 (2000) 236-244.
48. J.E. Staunton, D.K. Slonim, H.A. Coller, P. Tamayo, M.J. Angelo, J. Park, U. Scherf, J.K. Lee, J.N. Weinstein, J.P. Mesirov, E.S. Lander, T.R. Golub, Chemosensitivity prediction by transcriptional profiling, Proc. Natl Acad. Sci. USA 98 (2001) 10787-10792.
49. D. Shalon, S.J. Smith, P.O. Brown, A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization, Genome Res. 6 (1996) 639-645.
50. J.K. Lee, U. Scherf, K.J. Bussey, F.G. Gwadry, W.C. Reinhold, G. Riddick, J.N. Weinstein, Comparing cDNA and oligonucleotide array data: Concordance of gene expression across platforms for the NCI-60 cancer cell lines, Proc. Natl Acad. Sci. USA (submitted).
51. T.G. Myers, J.N. Weinstein, K. Raghavan, J.K. Buolamwini, N.L. Anderson, P. O'Connor, K.W. Kohn, D.A. Scudiero, A.P. Monks, S. Friend, D. Zaharevitz, L.V. Rubinstein, K.D. Paull, An "information intensive" strategy for drug discovery in cancer and AIDS: relating cell cycle factors to patterns of drug activity, Proc. Am. Assoc. Cancer Res. 36 (1995) A1813.
52. L. Tanabe, L.H. Smith, J.K. Lee, U. Scherf, L. Hunter, J.N. Weinstein, MedMiner: An internet tool for mining information, with application to gene expression profiling, BioTechniques 27 (1999) 1210-1217.
53. K.J. Bussey, D. Kane, M. Sunshine, S. Narasimhan, S. Nishizuka, W.C. Reinhold, B. Zeeberg, Ajay and Weinstein J.N., MatchMiner: A tool for batch navigation among gene and gene product identifiers, Genome Biol., in press.
54. B. Zeeberg, W. Feng, G. Wang, M.D. Wang, A.T. Fojo, D.W. Kane, W.C. Reinhold, J.N. Weinstein, GoMiner: A resource for biological interpretation of genomic and proteomic data, Genome Biol., in press.
55. P.E. Blower, C. Yang, M.A. Fligner, J.S. Verducci, L. Yu, S. Richman, J.N. Weinstein, Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data, Pharmacogenomics J. (Nature) 2 (2002) 259-271.